Impact of HPV Vaccine On The Prevalence Of Human Papillomavirus In Mouth And Vagina In Norway
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cervical Intraepithelial Neoplasia
- Sponsor
- Oslo University Hospital
- Enrollment
- 315
- Locations
- 1
- Primary Endpoint
- Vaginal and oral HPV-6, HPV-11, HPV-16 and HPV-18 prevalence
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The overall aim of the study is to assess the effect of school-based Human Papillomavirus (HPV) vaccination by comparing type-specific HPV prevalence between vaccinated and non-vaccinated women born in 1997. Women born in 1997, residence to Norway in 2009 (the year of vaccine initiation of the 1997-cohort) are invited to participate in the study.
Detailed Description
This cohort is amongst the first that was offered HPV vaccine in an organized vaccination programme globally. The women will be recruited through Facebook ads. The study will enable us to measure differences in the prevalence of HPV types in vagina and the mouth between vaccinated and non-vaccinated young women in Norway. The womens vaccination status will be validated by linkage to the Norwegian Immunisation Registry (SYSVAK) and their residence status will be validated through linkage to the Norwegian Population Registry.
Investigators
Espen Enerly
Dr Scient
Oslo University Hospital
Eligibility Criteria
Inclusion Criteria
- •Born in 1997
- •Resident of Norway in 2009
Exclusion Criteria
- •Born before or after 1997
- •Non-resident of Norway in 2009
Outcomes
Primary Outcomes
Vaginal and oral HPV-6, HPV-11, HPV-16 and HPV-18 prevalence
Time Frame: Within 2 months after self-collection of specimens
The differences in HPV types prevalence among vaccinees and non-vaccinees. HPV types will be assessed individually and combined.
Secondary Outcomes
- Description of oral and vaginal overall genotype distribution among vaccinated and non-vaccination participants(Within 2 months after self-collection of specimens)